Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating ivosidenib for the treatment of acute myeloid leukemia.

Expert opinion on pharmacotherapy - 1 Dec 2020

Donker M L, Ossenkoppele G J

Abstract excerpt

INTRODUCTION: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, but the results for patients with AML are still unsatisfactory. The discovery of new mutations in AML, including IDH mutations, has opened the door for treatment with targeted agents. Ivosidenib is a selective, potent inhibitor of the IDH1 mutant protein. AREAS COVERED: This review summarizes the mechanism of action,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Treatment Outcome
Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Pyridines

Source

Identifiers

PMID: 32808831
DOI: 10.1080/14656566.2020.1806822

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating ivosidenib for the treatment of acute myeloid leukemia.PMID 32808831Read ↗

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Ivosidenib in acute myeloid leukemia.Semantic proximity Read ↗

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.Semantic proximity Read ↗

IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.Semantic proximity Read ↗

Prognostic Implications and Therapeutic Landscape of IDH1-Mutated AML: An Updated Review of Evidence and Indian Perspective.Semantic proximity Read ↗

Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.